Gene Logic Provides Update on Business Review

Gene Logic Inc. (NASDAQ:GLGC) today announced findings
of the business review it has conducted over the last 90 days.

   Drug Repositioning: Gene Logic's recent business review has
confirmed the potential for its Drug Repositioning business to
significantly enhance long-term shareholder value. Market research
conducted by a leading strategy consulting firm has validated large
pharmaceutical companies' interest in the emerging field of drug
repositioning as an important option for obtaining new, late stage R&D
pipeline drug candidates. Gene Logic believes its approach to
repositioning high-quality drug candidates that stalled in clinical
development for reasons other than toxicity could, in many cases,
enable these candidates to return directly into Phase II clinical
development.
   Drug Repositioning agreements reached with Pfizer, Organon, and
Roche, as well as a number of active discussions underway with other
pharmaceutical companies, are evidence of the value the industry
places on Gene Logic's Drug Repositioning capability. Generally, these
agreements provide for significant milestone and royalty payments, and
several contain the option for Gene Logic to develop or co-develop
successfully repositioned drug candidates under certain conditions.
The Company believes it has made significant progress to date on a
number of candidates in the program. It is currently in discussion
with partners about which of these drug candidates may be appropriate
for further advancement.

   Genomics: The business review has confirmed that the Company's
prior strategy for its Genomics business, intended to compensate for
the impact of changing market conditions, will not reverse recent
sales trends. As a result, the Company undertook a number of
previously announced restructuring moves intended to reduce the use of
cash and lower expenses. These actions included the elimination of
over 80 positions and openings--including over 50% of its Genomics
workforce--the closure of the Company's Berkeley, California office,
and cut-backs in spending for related General and Administrative
expenses.
   The Company has retained the core competencies required to support
its current Genomics products and services, and expects not only to
support existing customers, but also to obtain new customers for these
products and services.
   The Genomics assets are a key part of the technology platform used
in the Company's Drug Repositioning business to find new therapeutic
uses for partners' drug candidates, and they will continue to be
leveraged in these efforts. Management has also concluded that the
assets and technologies of its Genomics business may have additional
value in areas such as clinical biomarker development and molecular
diagnostics. These and other options are being actively explored.

   Preclinical Services: Gene Logic's Preclinical Services business
continues to improve its financial performance. While the business is
not yet profitable, the Company expects operating margins to continue
to improve and losses to narrow as the substantially increased pace of
new business signings leads to growth in revenue. As a result of
recent facilities expansions, sufficient capacity exists for growth in
the near-term.

   Gene Logic Overview

   Gene Logic technologies and services are used by many of the
world's top pharmaceutical and biotechnology companies. Over 150
organizations and government agencies have benefited from Gene Logic's
diverse portfolio of drug development services, enabling them to make
more informed, more reliable and more predictive decisions at each
point in the highly complex and costly drug development process.
Founded in 1994, Gene Logic is headquartered in Gaithersburg,
Maryland, conducts additional research and development in facilities
in Cambridge, Massachusetts, and has customer support operations in
the U.S., Europe, and Asia.

   Safe Harbor Statement

   This press release contains "forward-looking statements," as such
term is used in the Securities Exchange Act of 1934, as amended. Such
forward looking statements include the Company's ability to identify
strategies for making its businesses successful and the impact of such
strategies on our business and financial performance and on
shareholder value. Forward-looking statements typically include the
words "expect," "anticipate," "believe," "estimate," "intend," "may,"
"will," and similar expressions as they relate to Gene Logic or its
management. Forward-looking statements are based on our current
expectations and assumptions, which are subject to risks and
uncertainties. They are not guarantees of our future performance or
results. Our actual performance and results could differ materially
from what we project in forward-looking statements for a variety of
reasons and circumstances, including particularly such risks and
uncertainties that may affect the Company's operations, financial
condition and financial results and that are discussed in detail in
the Company's Annual Report on Form 10-K and our other subsequent
filings with the Securities Exchange Commission. Such risks and
uncertainties include, but are not limited to: whether we will be able
to identify and successfully implement strategies, on favorable terms
or at all, for improving the performance and value of our businesses
and improving the value of our businesses to shareholders; whether we
will be able successfully to manage our existing cash adequately and
whether we will be able to generate sufficient cash from operations or
otherwise and to have access to financing on sufficiently favorable
terms to maintain our businesses and effect our strategies; whether we
will be able to recruit and retain qualified personnel, particularly
in light of our restructuring efforts; potential negative effects on
our operations and financial results from workforce reductions, other
restructuring activities, and the evaluation of strategic options; the
potential loss of significant customers; and the possibility of
delisting from NASDAQ Global Markets, which could have an adverse
effect on the value of our stock. Gene Logic undertakes no obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.